Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Säo Paulo med. j ; 138(4): 282-286, July-Aug. 2020. tab
Article in English | SES-SP, LILACS, SES-SP | ID: biblio-1139706

ABSTRACT

ABSTRACT BACKGROUND: Very few data are available for evaluating health-related quality of life among people with irritable bowel syndrome (IBS) and even fewer data are available in relation to anxiety and depression status among these patients. OBJECTIVES: To evaluate the quality of life, anxiety and depression status of patients with IBS. DESIGN AND SETTING: Observational cohort study conducted in a tertiary-care university hospital. METHODS: Patients who had recently been diagnosed with IBS and who had been followed up for IBS-specific treatment for at least three months were included. A quality of life (QoL) survey, the Beck Anxiety Index (BAI) and the Hamilton Depression Index (HAM-D) were applied to the patients. RESULTS: In total, 274 patients with IBS were included in the study cohort. These patients presented very high baseline scores for anxiety and depression, and very poor QoL results. CONCLUSION: Our study showed that IBS had a very high impact on these patients, regarding their anxiety and depression levels, alongside very poor results relating to quality of life.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Anxiety/epidemiology , Quality of Life/psychology , Irritable Bowel Syndrome/psychology , Depression/epidemiology , Anxiety/diagnosis , Psychiatric Status Rating Scales , Psychometrics , Surveys and Questionnaires , Cohort Studies , Irritable Bowel Syndrome/diagnosis , Depression/diagnosis
2.
Evid. actual. práct. ambul ; 23(1): e002045, 2020. tab
Article in Spanish | LILACS | ID: biblio-1103172

ABSTRACT

Una mujer de 36 años, diagnosticada con síndrome de intestino irritable a predominio de diarrea (SII-D) acude a la consulta médica. Ella pregunta si el uso de probióticos sería útil para controlar los episodios de diarrea, ya que los fármacos con los que está siendo tratada no le resultan eficaces. Se realizó una búsqueda bibliográfica con el objetivo de en contrar evidencia en respuesta a su consulta, tras la cual se seleccionaron dos ensayos clínicos y una revisión sistemática. Se evidenciaron diversos resultados en cuanto al uso de probióticos en el SII-D y se discutieron los riesgos y beneficios del tratamiento, así como las implicancias en la vida de la paciente. (AU)


A 36-year-old woman diagnosed with diarrhea predominant irritable bowel syndrome (D-IBS) goes to meet the doctor. She raises whether the use of probiotics would be useful for controlling diarrhea episodes, since the drugs which she is being treated with, are not effective. A bibliographic search was conducted with the objective of finding evidence in response toher query. Two clinical trials and a systematic review were found. Variable results were found regarding the use of probioticsin D-IBS. The risks and benefits of the treatment were discussed, as well as the implications in the patient's lifestyle. (AU)


Subject(s)
Humans , Female , Adult , Probiotics/therapeutic use , Irritable Bowel Syndrome/therapy , Diarrhea/therapy , Parasympatholytics/therapeutic use , Quality of Life , Review Literature as Topic , Abdominal Pain/therapy , Cholestyramine Resin/therapeutic use , Clinical Trials as Topic , Probiotics/administration & dosage , Probiotics/adverse effects , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/etiology , Diarrhea/complications , Duration of Therapy , Gastrointestinal Motility/immunology , Intestinal Mucosa/immunology , Loperamide/therapeutic use , Antidepressive Agents/therapeutic use
3.
Rev. Hosp. Clin. Univ. Chile ; 29(2): 166-172, 2018. graf
Article in Spanish | LILACS | ID: biblio-986840

ABSTRACT

Differentiation between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be complex as their symptoms are often similar and unspecific. Fecal biomarkers could be useful to select patients with suspected organic diseases for colonoscopy, with the aim to improve early diagnosis and to avoid unnecessary invasive studies. Fecal calprotectin (FC) is a protein found mainly in neutrophils that is released into the feces as a result of cell disruption and apoptosis. Currently, FC is a simple and non-invasive biomarker of intestinal inflammation. Inflammatory gastrointestinal disorders are associated with high levels of FC, as occurs in IBD. This review focuses on FC as a useful tool for differential diagnosis between IBS and IBD in adults. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Inflammatory Bowel Diseases/diagnosis , Leukocyte L1 Antigen Complex/analysis , Irritable Bowel Syndrome/diagnosis , Feces/chemistry
4.
Egyptian Journal of Hospital Medicine [The]. 2018; 71 (2): 2581-2584
in English | IMEMR | ID: emr-192501

ABSTRACT

Background: despite the modern society and medical knowledge, irritable bowel syndrome has been common these days in medical students in Hail city


Objectives: irritable bowel syndrome [IBS] is a common gastrointestinal disease presenting with abdominal pain, bloating and change in bowel habit. This study aims to assess the prevalence of irritable bowel syndrome in medical students in Hail's university, Saudi Arabia


Methods: a cross-sectional study on the prevalence of irritable bowel syndrome was randomly distributed among men and women in Hail University in Hail city, of Saudi Arabia from January to February 2018 involving 133 medical student participants


Results: in 18% of the participants have been diagnosed with IBS and 28.5% fit Rome IV criteria for the diagnosis of IBS. Stress with a percentage of 69.2% and lack of exercise 75.9% being the highest risk factors of IBS


Conclusion: our result showed that huge number of medical students are suffering from inflammatory bowel syndrome


Subject(s)
Humans , Male , Female , Adult , Irritable Bowel Syndrome/diagnosis , Students, Medical , Prevalence , Cross-Sectional Studies
5.
Yonsei Medical Journal ; : 146-152, 2016.
Article in English | WPRIM | ID: wpr-186110

ABSTRACT

PURPOSE: Recent studies have revealed close relationships between hepatic injury, metabolic pathways, and gut microbiota. The microorganisms in the intestine also cause irritable bowel syndrome (IBS). The aim of this study was to examine whether IBS was associated with elevated hepatic enzyme [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)], gamma-glutamyl transferase (gamma-GT) levels, and metabolic syndrome (MS). MATERIALS AND METHODS: This was a retrospective, cross-sectional, case-control study. The case and control groups comprised subjects who visited our health promotion center for general check-ups from June 2010 to December 2010. Of the 1127 initially screened subjects, 83 had IBS according to the Rome III criteria. The control group consisted of 260 age- and sex-matched subjects without IBS who visited our health promotion center during the same period. RESULTS: Compared to control subjects, patients with IBS showed significantly higher values of anthropometric parameters (body mass index, waist circumference), liver enzymes, gamma-GT, and lipid levels. The prevalences of elevated ALT (16.9% vs. 7.7%; p=0.015) and gamma-GT (24.1% vs. 11.5%; p=0.037) levels were significantly higher in patients with IBS than in control subjects. A statistically significant difference was observed in the prevalence of MS between controls and IBS patients (12.7% vs. 32.5%; p<0.001). The relationships between elevated ALT levels, MS, and IBS remained statistically significant after controlling for potential confounding factors. CONCLUSION: On the basis of our study results, IBS may be an important condition in certain patients with elevated ALT levels and MS.


Subject(s)
Adult , Alanine Transaminase/analysis , Aspartate Aminotransferases/analysis , Body Mass Index , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Irritable Bowel Syndrome/diagnosis , Liver/metabolism , Male , Metabolic Syndrome/complications , Middle Aged , Obesity/epidemiology , Prevalence , Retrospective Studies , Waist Circumference , gamma-Glutamyltransferase/analysis
6.
Rev. colomb. gastroenterol ; 30(supl.1): 43-56, oct.-dic. 2015. ilus
Article in Spanish | LILACS, BIGG | ID: lil-776326

ABSTRACT

Objetivo: diseñar una guía de práctica clínica para disminuir la variabilidad injustificada en el diagnóstico y tratamiento de los pacientes mayores de 18 años con síndrome de intestino irritable en Colombia mediante un diagnóstico orientado y unas pautas terapéuticas establecidas. Materiales y métodos: el equipo multidisciplinario que conformó el presente Grupo Desarrollador contó con apoyo de la Asociación Colombiana de Gastroenterología, el Grupo Cochrane ITS y el Instituto de Investigaciones Clínicas de la Universidad Nacional de Colombia. Se desarrollaron preguntas clínicas relevantes y se realizó la búsqueda de guías nacionales e internacionales en bases de datos especializadas. Las guías existentes fueron evaluadas en términos de calidad y aplicabilidad; ninguna de ellas cumplió el criterio de adaptación, por lo que se decidió desarrollar una guía de novo. El Grupo Cochrane realizó la búsqueda sistemática de la literatura. Las tablas de evidencia y recomendaciones fueron realizadas usando la metodología GRADE. Resultados: se desarrolló una guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento farmacológico de los pacientes mayores de 18 años con síndrome de intestino irritable en Colombia. Conclusiones: se establecieron los criterios clínicos y signos de alarma, las pruebas diagnósticas y las aproximaciones terapéuticas de acuerdo con el síntoma predominante en los pacientes con síndrome de intestino irritable en Colombia.


Objective: To design a clinical practice guideline to reduce unwarranted variation in the diagnosis and treatment of patients over 18 years old with irritable bowel syndrome in Colombia through targeted diagnosis and a treatment guidelines established. Materials and Methods: This guide was developed by a multidisciplinary team with the support of the Colombian Association of Gastroenterology, Cochrane STI Group and Clinical Research Institute of the Universidad Nacional de Colombia. Relevant clinical questions were developed and the search for national and international guidelines in databases was performed. Existing guidelines were evaluated quality and applicability. No guideline met the criteria for adaptation, so the group decided to develop the guideline de novo. Systematic literature searches were conducted by the Cochrane Group. The tables of evidence and recommendations were made based on the GRADE methodology. Results: An evidence-based Clinical Practice Guidelines for the diagnosis and treatment of irritable bowel syndrome in patients over 18 years old was developed for the Colombian context. Conclusions: the clinical criteria and warning signs, diagnostic tests and therapeutic approaches were established in accordance with the predominant symptom in patients with irritable bowel syndrome in Colombia.


Subject(s)
Humans , Adult , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/therapy
7.
Säo Paulo med. j ; 133(4): 343-349, July-Aug. 2015. graf
Article in English | LILACS | ID: lil-763369

ABSTRACT

CONTEXT AND OBJECTIVE:The presence of a certain degree of inflammation in the gut wall is now accepted in irritable bowel syndrome (IBS). Fecal calprotectin is considered to be a reliable test for detecting intestinal inflammation. Our aim was to assess the presence of inflammation in postinfectious IBS (PI-IBS), compared with non-postinfectious IBS (NPI-IBS). A secondary objective was to determine the usefulness of a rapid fecal calprotectin test in inflammatory bowel diseases (IBD).DESIGN AND SETTING:This was a cross-sectional study. Patients with IBS and IBD at a single tertiary gastroenterology center were prospectively included in this study.METHODS:116 patients with Rome III IBS score (76 females; 48 ± 12 years) were investigated; 24 patients (15 females) had PI-IBS. Intestinal inflammation was assessed using the semiquantitative fecal calprotectin test. The results were expressed as T1, T2 or T3 according to the severity of inflammation (< 15 μg/g; 15-60 μg/g; > 60 μg/g). Using the same test, we evaluated 20 patients with IBD (12 males; 47 ± 13 years).RESULTS:None of the patients with IBS had a T2 or T3 positive test. Among PI-IBS patients, 33% had a T1 positive test. Among NPI-IBS patients, 9.8% had a T1 positive test, which was significantly different to PI-IBS. The calprotectin test was positive in all IBD patients: 80% with T3, 10% with T2 and 10% with T1.CONCLUSIONS:Using a semiquantitative test for fecal calprotectin, positive tests were more frequent in PI-IBS patients than in NPI-IBS patients.


CONTEXTO E OBJETIVO:A presença de certo grau de inflamação na parede do intestino é agora aceita na síndrome do intestino irritável (SII). A calprotectina fecal é considerada teste confiável para detectar inflamação intestinal. Nosso objetivo foi avaliar a presença de inflamação na SII pós-infecciosa (SII-PI), em comparação com a SII não pós-infecciosa (SII-NPI). Um objetivo secundário foi determinar a utilidade de um teste rápido fecal da calprotectina em doenças inflamatórias intestinais (DII).TIPO DE ESTUDO E LOCAL:Este foi um estudo transversal. Pacientes com SII e DII em um único centro terciário de gastroenterologia foram prospectivamente incluídos neste estudo.MÉTODOS:116 pacientes com escore Roma III de SII (76 mulheres, 48 ± 12 anos) foram investigados; 24 pacientes (15 mulheres) tinham SII-PI. Inflamação intestinal foi avaliada pelo teste semi-quantitativo de calprotectina fecal. Os resultados foram expressos como T1, T2 ou T3 de acordo com a gravidade da inflamação (< 15 μg/g; 15-60 mg/g; > 60 mg/g). Usando o mesmo teste, foram avaliados 20 pacientes com DII (12 homens, 47 ± 13 anos).RESULTADOS:Nenhum dos pacientes com SII teve um teste positivo T2 ou T3. Na PI-IBS, 33% tiveram um teste positivo T1. Entre os pacientes SII-NPI, teste T1 positivo estava presente em 9,8%, taxa significativamente diferente quando comparada com SII-PI. O teste de calprotectina foi positivo em todos os pacientes com DII: 80% com T3, 10% com T2 e 10% com T1.CONCLUSÕES:Usando teste semi-quantitativo para calprotectina fecal, relatamos positividade em pacientes SII-PI com mais frequência que em pacientes SII-NPI.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Feces/chemistry , Gastroenteritis/diagnosis , Inflammatory Bowel Diseases/diagnosis , Irritable Bowel Syndrome/diagnosis , Leukocyte L1 Antigen Complex/analysis , Biomarkers/analysis , Cross-Sectional Studies , Diagnosis, Differential , Gastroenteritis/complications , Irritable Bowel Syndrome/complications , Leukocyte L1 Antigen Complex/economics , Pilot Projects , Prospective Studies , Sensitivity and Specificity
8.
Rev. méd. Chile ; 143(5): 619-626, ilus, tab
Article in Spanish | LILACS | ID: lil-751708

ABSTRACT

Remission of gastrointestinal and general symptoms after gluten withdrawal has been described in some non-celiac individuals for nearly 30 years. Only recently, efforts have been made to define this entity, now referred to as "non- celiac gluten sensitivity". It includes patients that clinically respond to gluten free diet without exhibiting allergic or autoimmune features to explain such response. Wheat allergy, celiac disease, irritable bowel syndrome and symptoms induced by high FODMAPs (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols) consumption are the main differential diagnoses. The relationship with neuropsychiatric disorders such as schizophrenia and autism has not been demonstrated, but currently it gives ground to great hope in families with affected children. Epidemiology of non-celiac gluten sensitivity is not clear. It is described as more common among women and less common in children. Genetic and immune factors, changes in intestinal microbiota and non-gluten components present in wheat grains are main factors postulated in the pathogenesis of this condition. To date, there are no specific biomarkers for non-celiac gluten sensitivity and diagnosis is reached by excluding other causes of disease. A trial with gluten-free diet and subsequent gluten challenge is the methodology most frequently used to confirm diagnosis.


Subject(s)
Humans , Food Hypersensitivity/diagnosis , Glutens/adverse effects , Autistic Disorder/etiology , Autistic Disorder/psychology , Celiac Disease/diagnosis , Celiac Disease/physiopathology , Diagnosis, Differential , Diet, Gluten-Free/methods , Food Hypersensitivity/complications , Food Hypersensitivity/diet therapy , Food Hypersensitivity/physiopathology , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/physiopathology , Schizophrenia , Wheat Hypersensitivity/complications
9.
Arq. gastroenterol ; 52(1): 50-54, Jan-Mar/2015. tab, graf
Article in English | LILACS | ID: lil-746478

ABSTRACT

Background Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit Results A total of 279 patients were included in the study, with median age of 39 years (range, 18 to 78 years). After clinical and laboratorial evaluation and considering the final diagnosis, patients were allocated into the following groups: a) Irritable Bowel Syndrome: 154 patients (102 female and 52 male subjects). b) Inflammatory Bowel Diseases group: 112 patients; 73 with Crohn’s disease; 38 female and 35 male patients; 52.1% (38/73) presented active disease, and 47.9% (35/73) had disease in remission and 39 patients with ulcerative colitis;19 female and 20 male patients; 48.7% (19/39) classified with active disease and 49.3% (20/39) with disease in remission. A significant difference (P<0.001) was observed between the median value of fecal calprotectin in Irritable Bowel Syndrome group that was 50.5 µg/g (IQR=16 - 294 µg/g); 405 µg/g (IQR=29 - 1980 µg/g) in Crohn’s disease patients and 457 µg/g (IQR=25 - 1430 µg/g) in ulcerative colitis patients. No difference was observed between the values found in the patients with Crohn’s disease and ulcerative colitis. Levels of fecal calprotectin were significantly ...


Contexto A calprotectina fecal é um biomarcador que pode fornecer informações importantes para o médico, inclusive no atendimento primário, no diagnóstico diferencial de distúrbios gastrointestinais, principalmente as doenças inflamatórias intestinais e a síndrome do intestino irritável. Objetivos Investigar prospectivamente, em adultos brasileiros com queixas gastrointestinais, o valor da calprotectina fecal como biomarcador para o diagnóstico diferencial de distúrbios funcionais e orgânicos e correlacionar as concentrações com a atividade de doenças inflamatórias intestinais. Método O estudo incluiu pacientes consecutivos que apresentavam queixas gastrointestinais e que a dosagem da calprotectina fecal foi recomendada. A dosagem da calprotectina fecal foi obtida utilizando-se o kit ELISA Buhlmann, (Basel, Suiça). Resultados Um total de 279 foram incluídos no estudo, com idade média de 39 anos (variando entre 18 a 78 anos). Após avaliação clínica e laboratorial, e considerando o diagnóstico final, os pacientes foram alocados nos seguintes grupos: a) Grupo Síndrome do Intestino Irritável: 154 pacientes (102 do sexo feminino e 52 indivíduos do sexo masculino). b) grupo Doenças Inflamatórias Intestinais: 112 pacientes; 73 com doença de Crohn; 38 do sexo feminino e 35 pacientes do sexo masculino; 52,1% (38/73) apresentavam doença ativa, e 47,9% (35/73) tiveram a doença em remissão e 39 pacientes com retocolite ulcerativa; 19 do sexo feminino e 20 pacientes do sexo masculino; 48,7% (19/39) classificadas com a doença ativa e 49,3% (20/39) com a doença em remissão. Foi observada uma diferença significativa (P<0,001) entre o valor médio de calprotectina fecal no grupo Síndrome do Intestino Irritável que foi de 50,5 µg/g (16 a 294 µg/g); 405 µg/g (29 a 1980 µg/g), em pacientes com doença de Crohn e 457 µg/g (25 a1430 µg/g), em pacientes com retocolite ulcerativa. Não foram observadas diferenças entre os valores encontrados nos pacientes com ...


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Feces/chemistry , Inflammatory Bowel Diseases/diagnosis , Irritable Bowel Syndrome/diagnosis , Leukocyte L1 Antigen Complex/analysis , Brazil , Biomarkers/analysis , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Prospective Studies
10.
Article in English | WPRIM | ID: wpr-146122

ABSTRACT

Small intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated IBS patients. However, there are few reports on the association of the rifaximin treatment periods with the results of a lactulose breath test (LBT). Therefore, we performed a retrospective review of patient charts to investigate the relation between the rifaximin treatment periods with LBT results in nonconstipated IBS patients. We also evaluated the time to achieve a symptomatic improvement in the IBS patients as compared to the changes in the LBT. We reviewed the charts for patients who showed IBS symptoms with documented positive results for LBT during their initial visit and who had a follow-up LBT after treatment with rifaximin. The LBT values were compared to the subjects' symptom scores. A total of 102 subjects had a follow-up LBT to assess LBT normalization. The subjects were divided into groups according to treatment periods of 4 weeks (n = 36), 8 weeks (n = 43), and 12 weeks (n = 23). The groups with a longer treatment exhibited an increase in the hydrogen gas value at 90 min and its sum during 90 min at the initial LBT. There were significant differences in hydrogen gas value at 90 min and in its sum during 90 min at the initial LBT between the groups treated for 4 and 12 weeks. The most significant treatment response was observed during the first 4 weeks for all treatment groups. Symptomatic improvement occurred earlier than LBT normalization in the treatment period over 4 weeks. The results indicate that different rifaximin treatment periods are needed in accordance with LBT levels to effectively eradicate SIBO.


Subject(s)
Biomarkers/analysis , Breath Tests/methods , Constipation , Drug Administration Schedule , Drug Monitoring/methods , Female , Gastrointestinal Agents/administration & dosage , Humans , Irritable Bowel Syndrome/diagnosis , Lactulose/analysis , Male , Middle Aged , Reproducibility of Results , Rifamycins/administration & dosage , Sensitivity and Specificity , Treatment Outcome
11.
GEN ; 67(3): 139-144, sep. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-702766

ABSTRACT

El síndrome del intestino irritable (SII) es un trastorno digestivo funcional que afecta del 10 al 20% de la población general. Existen pocos estudios en Latinoamérica que muestren su prevalencia nacional, y en Venezuela no disponemos de investigación que reporte tan importante cifra. Estudio multicéntrico, descriptivo, transversal, durante los meses abril y mayo del 2011. Se utilizó el cuestionario validado de la Fundación Roma, con quienes firmamos convenio como Servicio de Gastroenterología del Hospital Vargas de Caracas. Se seleccionaron al azar 15 estados, en cada uno un municipio, y de estos lugares como iglesias, centros comerciales, reuniones de Consejos Comunales, paradas de autobuses, etc. Los valores obtenidos fueron transcritos en una base de datos en Excel y procesados con EPIDAT 3.1. De 1781 personas encuestadas, 299 presentaron criterios clínicos diagnósticos para SII de acuerdo a Roma III. La prevalencia nacional del SII fue de 16,80%, correspondiendo 81,6% a mujeres (244) y 18,4% a hombres (55). El grupo etario entre 38 y 47 años fue el más afectado (26,43%) y el subtipo mixto el más predominante. La prevalencia del SII en la población adulta venezolana según los criterios de Roma III es de 16,80%


Irritable bowel syndrome (IBS) is a functional digestive disorder that affects 10 to 20% of the general population. Few studies exist in Latin America that shows the national prevalence, and in Venezuela we don´t have investigation resources that support those numbers. Multicenter study, descriptive, transversal, during the months April and May 2011. The validated Roma Foundation questionnaire was used. This Foundation authorized its use by the Service of Gastroenterology Hospital Vargas de Caracas. 15 states were randomly selected, in each state one municipality, and in those places as churches, shopping centers, comunity meeting, bus stops, etc. The values obtained were transcribed into a database in Excel and processed EPIDAT 3.1. Of 1781 people encuested, 299 met the criteria for IBS according to Rome III. The national prevalence of IBS was 16.80%, with 81.6% women (244) and 18.4% men (55). The age group between 38 and 47 years was the most affected (26.43%) and the mix was the most predominant subtype. The prevalence of IBS in the Venezuelan adult population according to Rome III criteria is 16.80%


Subject(s)
Female , Cross-Sectional Studies/methods , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/epidemiology , Gastroenterology
12.
Article in Korean | WPRIM | ID: wpr-126027

ABSTRACT

PURPOSE: This article provides an update and overview of a nursing research program focused on understanding the pathophysiology and management of irritable bowel syndrome (IBS). METHODS: This review includes English language papers from the United States, Europe, and Asia (e.g., South Korea) from 1999 to 2013. We addressed IBS as a health problem, emerging etiologies, diagnostic and treatment approaches and the importance of a biopsychosocial model. RESULTS: IBS is a chronic, functional gastrointestinal disorder characterized by recurrent episodes of abdominal pain and alterations in bowel habit (diarrhea, constipation, mixed). It is a condition for which adults, particularly women ages 20-45, seek health care services in both the United States and South Korea. Clinically, nurses play key roles in symptom prevention and management including designing and implementing approaches to enhance the patients' self-management strategies. Multiple mechanisms are believed to participate in the development and maintenance of IBS symptoms including autonomic nervous system dysregulation, intestinal inflammation, intestinal dysbiosis, dietary intolerances, alterations in emotion regulation, heightened visceral pain sensitivity, hypothalamic-pituitary-adrenal dysregulation, and dysmotility. Because IBS tends to occur in families, genetic factors may also contribute to the pathophysiology. Patients with IBS often report a number of co-morbid disorders and/or symptoms including poor sleep. CONCLUSION: The key to planning effective management strategies is to understand the heterogeneity of this disorder. Interventions for IBS include non-pharmacological strategies such as cognitive behavior therapy, relaxation strategies, and exclusion diets.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Clinical Nursing Research , Female , Humans , Immunosuppressive Agents/therapeutic use , Irritable Bowel Syndrome/diagnosis , Self Care
13.
Gastroenterol. latinoam ; 24(1): 14-19, 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-763433

ABSTRACT

Background: Intestinal pathology has a wide spectrum of symptoms, when these are unspecific endoscopic study is generally required in order to differentiate organic and functional disease. Fecal calprotectin (FC) is a reliable and non-invasive tool that can be used to infer damage in the intestinal mucosa, especially in Inflammatory Bowel Disease (IBD). Objective: To evaluate our initial experience measuring FC and its usefulness in medical practice. Materials and Methods: Using information of patients with FC indicated for unspecific gastrointestinal (GI) symptoms between January 2011 and March 2012. Patients were classified in: group 1 (G1 with IBD) and group 2 (without organic GI disease). Three groups were established according to FC results: negative (< 15 ug/g), intermediate (15-60 ug/g) and positive (> 60 ug/g). Concordance between results and physicians’ behavior was established. Results: In the period mentioned above a total of 64 patients (24 G1-40 G2) were selected. In G1, FC levels were negative, intermediate and positive in 8, 3 and 13 patients, respectively, being concordant in a 100, 100 and 84.6 percent, respectively. Only four patients needed a colonoscopy to adjust treatment. Mainly, there was a favorable clinical response. In G2, results on FC were negative in 19, intermediate in 8 and positive in 13 patients, in which concordance was established with the presence of organic intestinal pathology with a 94.7 percent, 87.5 percent and 92.3 percent, respectively. Conclusions: This study confirms that in our population, there is a good correlation between FC results and physicians behavior, especially in patients with IBD.


Introducción: En pacientes con síntomas gastrointestinales (GI) inespecíficos, es difícil diferenciar entre patología orgánica y funcional, requiriendo muchas veces de estudios endoscópicos asociados. La calprotectina fecal (CF) ha demostrado ser un marcador confiable y menos invasivo en la evaluación de la inflamación de la mucosa intestinal, especialmente en enfermedad inflamatoria intestinal (EII). Objetivo: Evaluar la experiencia inicial en la medición de CF y su utilidad en la práctica clínica. Material y Métodos: Utilizando datos de pacientes sometidos a medición de CF secundario a síntomas GI inespecíficos, entre enero de 2011 y marzo de 2012. Se clasificó en: grupo 1 (G1 pacientes con diagnóstico de EII) y grupo 2 (G2 sin morbilidad GI). Se midió CF y según el resultado se establecieron tres grupos: negativo (< 15 ug/g), intermedio (15-60 ug/g), y positivo (> 60 ug/g). Se buscó concordancia entre CF y conducta médica. Resultados: Se seleccionaron 64 pacientes (24 G1 y 40 G2). En G1, los niveles de CF negativa, intermedia y positiva, fueron 8, 3 y 13 respectivamente. La conducta médica fue concordante en 100, 100 y 84,6 por ciento. Sólo 4 pacientes requirieron de colonoscopia para modificar tratamiento. La mayoría tuvo respuesta clínica favorable. En G2, los resultados fueron 19 negativos, 8 intermedios y 13 positivos, donde según hallazgo de patología orgánica hubo 94,7 por ciento, 87,5 por ciento y 92,3 por ciento, de concordancia con el resultado de CF respectivamente. Conclusión: Este estudio confirma que en nuestra población existe buena correlación entre el resultado de CF y la conducta médica, sobre todo en pacientes con EII.


Subject(s)
Humans , Male , Female , Child , Adolescent , Young Adult , Middle Aged , Leukocyte L1 Antigen Complex/analysis , Inflammatory Bowel Diseases/diagnosis , Feces/chemistry , Irritable Bowel Syndrome/diagnosis , Colitis, Ulcerative/diagnosis , Crohn Disease/diagnosis , Biomarkers
14.
Article in English | WPRIM | ID: wpr-159648

ABSTRACT

Whether hydrogen and methane gas produced during lactulose breath test (LBT) are associated with symptoms of irritable bowel syndrome (IBS) is not determined. We aimed to investigate whether hydrogen and methane on LBT are associated with IBS symptoms. Sixty-eight IBS patients meeting the Rome III criteria for IBS, and 55 healthy controls, underwent LBT. The IBS subjects recorded their customary gastrointestinal symptoms on a questionnaire using visual analogue scales. LBT positivity was defined to be above 20 ppm rise of hydrogen or 10 ppm rise of methane within 90 min. Gas amounts produced during LBT were determined by calculating area under the curve of hydrogen and methane excretion. Symptom severity scores were not different between the LBT (+) IBS and LBT (-) IBS subjects and also between methane producers and non-methane producers. Gas amounts produced during LBT were not associated with IBS symptoms, except a weak correlation between total gas amounts and a few IBS symptoms such as bloating (r = 0.324, P = 0.039), flatulence (r = 0.314, P = 0.046) and abdominal pain (r = 0.364, P = 0.018) only in LBT (+) IBS. In conclusion, hydrogen and methane gas on LBT are not useful for predicting the customary symptoms and subtypes of IBS.


Subject(s)
Abdominal Pain/etiology , Adult , Area Under Curve , Breath Tests , Female , Flatulence/etiology , Gases/analysis , Humans , Hydrogen/analysis , Irritable Bowel Syndrome/diagnosis , Lactulose/metabolism , Male , Methane/analysis , Middle Aged , ROC Curve , Risk Factors
16.
Rev. gastroenterol. Perú ; 32(4): 366-370, oct.-dic. 2012. tab
Article in Spanish | LIPECS, LILACS, LIPECS | ID: lil-692404

ABSTRACT

INTRODUCCION: El impacto de la diarrea crónica en el adulto mayor es desproporcionado por diversos factores provocando mayor morbilidad y mortalidad. OBJETIVO: Describir las principales características acerca de la diarrea crónica en los pacientes ancianos del hospital Nacional Edgardo Rebagliati (Lima-Perú) durante el periodo enero del 2005 a diciembre del 2011, METODO: Estudio descriptivo y retrospectivo en la cual se revisaron las historias clínicas de los pacientes adultos mayores con el diagnostico de diarrea crónica, vertiéndose los datos en una ficha de recolección. RESULTADOS: Se revisaron las historias clínicas de 202 pacientes. La edad media fue de 73,5±6,7 años, siendo la mayoría mujeres (57.43%). Las principales comorbilidades fueron las cardiovasculares (60,4%) y endocrinas (27,2%). El tiempo de enfermedad medio fue de 21.6 ± 13.6 semanas. Los exámenes más solicitados fueron hemograma, bioquímica (glucosa, urea y creatinina), albumina, coprofuncional, parasitologico y colonoscopia. El tipo de diarrea más frecuente fue organica (84,16%). Dentro de las principales causas se encontró a la colitis microscópica (35,15%), parasitosis (15,84%), síndrome de intestino irritable (14,85%) y sobrecrecimiento bacteriano (8,42%). CONCLUSIONES: Las causas más frecuentes de diarrea crónica en el anciano son colitis microscópica, parasitosis, síndrome de intestino irritable y sobrecrecimiento bacteriano.


INTRODUCTION: The impact of chronic diarrhea in the elderly is disproportionate by several factors causing increased morbidity and mortality. OBJECTIVE: To describe the main features about the chronic diarrhea in elderly patients from Edgardo Rebagliati Hospital (Lima-Peru) during the period January 2005 to December 2011, METHOD: A descriptive and retrospective study in which we reviewed the medical records of elderly patients with the diagnosis of chronic diarrhea, pouring in a data collection sheet. RESULTS: We reviewed the medical records of 202 patients. The mean age was 73.5 ± 6.7 years, with most women (57.43%). Major comorbidities were cardiovascular (60.4%) and endocrine (27.2%). The half time of illness was 21.6 ± 13.6 weeks. The most requested tests were CBC, biochemistry, albumin, coprofuncional, parasitological and colonoscopy. The most common type of diarrhea was the organic (84.16%). Among the main causes were found microscopic colitis (35.15%), parasites (15.84%), irritable bowel syndrome (14.85%) and bacterial overgrowth (8.42%). CONCLUSIONS: The most common causes of chronic diarrhea in the elderly are microscopic colitis, parasites, irritable bowel syndrome and bacterial overgrowth.


Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Diarrhea/etiology , Blind Loop Syndrome/complications , Blind Loop Syndrome/diagnosis , Chronic Disease , Colitis, Microscopic/complications , Colitis, Microscopic/diagnosis , Hospitals, Public , Intestinal Diseases, Parasitic/complications , Intestinal Diseases, Parasitic/diagnosis , Irritable Bowel Syndrome/complications , Irritable Bowel Syndrome/diagnosis , Peru , Retrospective Studies
17.
Rev. gastroenterol. Perú ; 32(2): 178-183, abr.-jun. 2012. tab, graf
Article in Spanish | LIPECS, LILACS, LIPECS | ID: lil-661413

ABSTRACT

INTRODUCCIÓN: ante la ausencia de medidas objetivas para realizar el diagnóstico de Síndrome de Intestino Irritable (SII) se plantea el uso de la hipersensibilidad visceral como marcador biológico de la enfermedad. OBJETIVO: evaluar la percepción de dolor durante la sigmoidoscopia flexible mediante el uso de una escala analógica visual del dolor en pacientes con SII, además de valorar la percepción del dolor como criterio diagnóstico de ayuda al SII mediante la sensibilidad, especificidad y eficiencia diagnóstica de un valor de corte. METODOLOGÍA: se realizó un estudio prospectivo, tipo casos y controles, en pacientes con indicación para estudio sigmoidoscópico con y sin SII, para valorar la percepción del dolor después del examen mediante el empleo de una escala analógica visual. Se evaluaron las diferencias y se confeccionó una curva ROC, además de establecer la sensibilidad, especificidad y eficiencia diagnóstica. RESULTADOS: Se analizaron 20 pacientes con SII y 20 controles. El score de percepción del dolor fue mayor en los pacientes SII comparados con los pacientes no SII (mediana, 52.5 vs 27.5, p=0.006). El área bajo la curva fue de 0.84, determinándose un punto de corte en ≥ 40mm con una sensibilidad, especificidad y eficiencia diagnóstica de 85%, 75% y 80% respectivamente. CONCLUSIONES: Los pacientes con SII experimentan mayor percepción del dolor durante la sigmoidoscopia. Un valor de percepción del dolor en ≥ 40mm puede predecir el diagnóstico del SII con una buena sensibilidad (85%) y especificidad (75%).


INTRODUCTION: Visceral hypersensitivity has been proposed as a biological marker of Irritable bowel syndrome (IBS). OBJECTIVE: To evaluate the pain perception during sigmoidoscopy using a visual analog scale of pain in patients with or without IBS, and to asess the pain perception as diagnostic criteria for IBS. We further assessed the sensitivity, specificity and diagnostic efficiency of pain scores to diagnose IBS. METHODS: A prospective case-control study in patients who underwent sigmoidoscopy for the evaluation of gastrointestinal symptoms. All patients completed Rome III criteria questionnaries and divided into two groups: IBS and non-IBS. All participants reported pain scores on visual analog scales after of study. Differences were evaluated. We calculated a receiver-operator characteristic curve (ROC), sensitivity, specificity and diagnostic efficiency. RESULTS: We analyzed 20 patients with IBS and 20 controls. The pain scores were higher in IBS patients compared with non-IBS patients (median, 52.5 vs. 27.5, p = 0.006). The area under the curve was 0.84, at pain score level of ≥ 40 mm with a sensivity, specificity and diagnostic efficiency of 85%, 75% ando 80%, respectively. CONCLUSIONS: The degree of pain perception was higher in IBS patients than in non-IBS patients during sigmoidoscopy. A score of pain perception in ≥ 40 mm may predict the diagnosis of IBS with good sensivity (85%) and specificity (75%).


Subject(s)
Humans , Male , Adult , Female , Middle Aged , Hypersensitivity , Pain Perception , Sigmoidoscopy , Irritable Bowel Syndrome/diagnosis , Prospective Studies , Case-Control Studies , Observational Studies as Topic
18.
GED gastroenterol. endosc. dig ; 31(2): 71-74, abr.-jun. 2012.
Article in Portuguese | LILACS | ID: lil-698377

ABSTRACT

Síndrome do Intestino Irritável (SII) é um transtorno funcional crônico do tubo digestivo, caracterizado pela presença de dor e/ou desconforto abdominal associados à alteração do hábito intestinal ou à modificação das características das evacuações. A sua etiologia permanece desconhecida, mas provavelmente é multifatorial. A prevalência estimada da SII na população geral é de 10 a 20%, acometendo predominantemente mulheres entre 20 e 40 anos. O diagnóstico é feito baseado na sintomatologia predominante, adotando-se critérios clínicos bem estabelecidos (Roma III). O tratamento visa aliviar o sintoma predominante. Os antiespasmódicos representam as drogas de primeira escolha para o alívio da dor e do desconforto abdominal. Os antidepressivos tricíclicos têm se mostrado superiores ao placebo para os pacientes com SII e predomínio de diarreia, e a loperamida é eficaz em reduzir a frequência das evacuações nestes casos. Para os pacientes com SII e predomínio de constipação ou forma mista, as fibras solúveis representam a primeira opção. Probióticos e novos serotoninérgicos representam outras opções terapêuticas promissoras. Relatamos o caso de uma paciente do sexo feminino portadora de SII com diarreia predominante.


Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract, characterized by abdominal pain and change in bowel habit, with a fluctuating natural history. The exact etiology remains unknown, but it is unlikely there is a single unifying explanation. IBS affects 10-20% of the general population, with women 20-40 years old accounting for the majority of patients. The diagnosis should be made on clinical grounds, using Rome III diagnostic criteria. The clinical approach is based on treatment of the prevalent symptom. When pain predominates, antispasmodics are the first choice. Tricyclic antidepressants are more effective than placebo for patients with diarrhea predominant IBS, and loperamide is useful for reducing bowel frequency in this patients. Soluble fiber represents the first option in subjects with IBS and constipation or mixed IBS. Dietary integrators composed of probiotics and serotonin precursors are a promising therapeutic option. We report a case of a female patient with IBS-diarrhea predominant.


Subject(s)
Humans , Female , Middle Aged , Irritable Bowel Syndrome , Abdominal Pain , Constipation , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/drug therapy , Diarrhea
19.
Article in English | IMSEAR | ID: sea-157390

ABSTRACT

Objective: To evaluate sympathetic adrenergic function in irritable bowel syndrome (IBS) patients. Methods: Standard cardiovascular reflex tests were performed on forty patients with IBS and thirty healthy subjects. Sympathetic adrenergic function was assessed by measuring diastolic blood pressure response to hand grip test (HGT) at 4 min and cold pressor test (CPT) at 1min and also blood pressure response to head-up-tilt (HUT). Results: The change in diastolic pressure during (HGT) and (CPT) of IBS patients were not significantly different when compared to control. However, tilting resulted in less marked rise in diastolic pressure (6.14 ± 0.69 vs 12.1 ± 1.24 mmHg; p < 0.05) at 0.5 min and less rise in heart rate (6.03 ± 1.26 vs 10.35 ± 1.04 per min; p < 0.05) at 1 min in IBS patients. Conclusion: IBS patients had reduced sympathetic drive to (HUT) stress; however, subgroups of IBS had similar autonomic reaction.


Subject(s)
Adult , Autonomic Nervous System/physiology , Blood Pressure/physiology , Cold Temperature , Female , Hand Strength/physiology , Humans , Hypertension/physiopathology , Irritable Bowel Syndrome/diagnosis , Irritable Bowel Syndrome/physiology , Male , Sympathetic Nervous System/physiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL